google plus one (home page)

The Weekly Dose: New Endocrine Guidelines, Digital Asthma Gains, AI Trust Gap, GLP-1 & Dementia Risk, First CHE Treatment

The accelerated approval for semaglutide 2.4 mg for the treatment of noncirrhotic MASH was based on part 1 of the phase 3 ESSENCE trial, which met its primary endpoints.

AHA/ACC Release Revised Hypertension Clinical Practice Guidelines to Reduce CVD Risk

Explore the latest insights on diabetes in pregnancy, asthma management disparities, AI in health care, dementia risk reduction, and new eczema treatments.

Guideline Topline: 2025 AHA/ACC Hypertension / image credit Dan Jones, MD, University of Mississippi Foundation

The Weekly Dose: Pediatric Vaccine Safety, Atopic Dermatitis, Dementia Risk, and Maternal Depression

Updates to the 2017 guideline focus on new monitoring strategies, earlier intervention to reduce cognitive decline, improved perinatal care, and refined risk assessment.

August 7th 2025

GLP-1 RAs Prescribed for More Than One-Third of US Adults With Diabetes in Middle Age: NCHS Data Brief

Insights on atopic dermatitis treatment preferences, the safety of childhood vaccines, maternal depression’s effect on parenting, and more.

GLP-1 RAs Prescribed for More Than One-Third of US Adults With Diabetes in Middle Age: NHIS Data Brief / image credit ©Sebastian Garcia/stock.adobe.com

Lecanemab Shows Sustained Benefit at 4 Years in Early Alzheimer Disease: Daily Dose

GLP-1 use among adults with diabetes peaked among those aged 50 to 64 years, was highest among Hispanic adults, and was more likely among those taking other antihyperglycemic agents.

FDA Approves Semaglutide 2.4 mg for Treatment of MASH Without Cirrhosis

Your daily dose of the clinical news you may have missed.

Related Content

Patient Care Editorial Staff

August 16th 2025

The Weekly Dose: New Endocrine Guidelines, Digital Asthma Gains, AI Trust Gap, GLP-1 & Dementia Risk, First CHE Treatment

The accelerated approval for semaglutide 2.4 mg for the treatment of noncirrhotic MASH was based on part 1 of the phase 3 ESSENCE trial, which met its primary endpoints.

AHA/ACC Release Revised Hypertension Clinical Practice Guidelines to Reduce CVD Risk

Explore the latest insights on diabetes in pregnancy, asthma management disparities, AI in health care, dementia risk reduction, and new eczema treatments.

The Weekly Dose: Pediatric Vaccine Safety, Atopic Dermatitis, Dementia Risk, and Maternal Depression

Updates to the 2017 guideline focus on new monitoring strategies, earlier intervention to reduce cognitive decline, improved perinatal care, and refined risk assessment.

August 7th 2025

GLP-1 RAs Prescribed for More Than One-Third of US Adults With Diabetes in Middle Age: NCHS Data Brief

Insights on atopic dermatitis treatment preferences, the safety of childhood vaccines, maternal depression’s effect on parenting, and more.

Lecanemab Shows Sustained Benefit at 4 Years in Early Alzheimer Disease: Daily Dose

GLP-1 use among adults with diabetes peaked among those aged 50 to 64 years, was highest among Hispanic adults, and was more likely among those taking other antihyperglycemic agents.